Masaya Akai
Overview
Explore the profile of Masaya Akai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Motoie R, Akai M, Kitahara T, Imamura H, Tanabe T, Sarazawa K, et al.
Intern Med
. 2020 Sep;
59(20):2597-2600.
PMID: 32893231
The relationship between coronavirus disease 2019 (COVID-19) and intracerebral hemorrhage remains unclear. We herein report a case of severe COVID-19 pneumonia complicated by multiple simultaneous intracerebral hemorrhages (MSICH). The patient...
12.
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med
. 2020 Jul;
59(23):3055-3059.
PMID: 32727989
A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but...
13.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, et al.
J Clin Med
. 2020 Jun;
9(6).
PMID: 32517152
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first-...
14.
Nakashima K, Demura Y, Oi M, Tabata M, Tada T, Shiozaki K, et al.
Intern Med
. 2020 Mar;
59(11):1433-1435.
PMID: 32161221
We herein report a 66-year-old woman with advanced lung adenocarcinoma [programmed cell death and its ligand 1 (PD-L1) tumor proportion score 60%] lacking driver oncogenes in whom meningeal carcinomatosis, along...
15.
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, et al.
Lung Cancer
. 2019 Aug;
135:175-180.
PMID: 31446992
Objectives: Afatinib is an effective treatment in patients who have epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), but its toxicities often require dose adjustment. Exploratory analyses of...
16.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, et al.
Oncologist
. 2019 Jan;
24(5):593-e170.
PMID: 30651400
Lessons Learned: Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M...
17.
Kanai O, Kim Y, Demura Y, Kanai M, Ito T, Fujita K, et al.
Thorac Cancer
. 2018 May;
9(7):847-855.
PMID: 29782069
Background: The risk of developing lung cancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used for the...
18.
Anzai M, Morikawa M, Okuno T, Umeda Y, Demura Y, Sonoda T, et al.
Medicine (Baltimore)
. 2018 Feb;
96(51):e9320.
PMID: 29390506
Background: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC)....
19.
Mizuno S, Ishizaki T, Kadowaki M, Akai M, Shiozaki K, Iguchi M, et al.
Chest
. 2017 Mar;
152(1):58-69.
PMID: 28315337
Background: The p53 signaling pathway may be important for the pathogenesis of emphysematous changes in the lungs of smokers. Polymorphism of p53 at codon 72 is known to affect apoptotic...
20.
Kato R, Mizuno S, Kadowaki M, Shiozaki K, Akai M, Nakagawa K, et al.
Respir Res
. 2016 Oct;
17(1):139.
PMID: 27784320
Background: Cigarette smoke induced oxidative stress has been shown to reduce silent information regulator 1 (Sirt1) levels in lung tissue from smokers and patients with COPD patients. Sirt1 is known...